SCI
17 October 2024
Defining precancer: a grand challenge for the cancer community
(IF: Nat Rev Cancer, 72.5)
Faupel-Badger J, Kohaar I, Bahl M, Chan AT, Campbell JD, Ding L, De Marzo AM, Maitra A, Merrick DT, Hawk ET, Wistuba II, Ghobrial IM, Lippman SM, Lu KH, Lawler M, Kay NE, Tlsty TD, Rebbeck TR, Srivastava S; Precancer Think Tank Team. Defining precancer: a grand challenge for the cancer community. Nat Rev Cancer. 2024 Oct 1.
Correspondence: srivasts@mail.nih.gov
The term ‘precancer’ typically refers to an early stage of neoplastic development that is distinguishable from normal tissue owing to molecular and phenotypic alterations, resulting in abnormal cells that are at least partially self-sustaining and function outside of normal cellular cues that constrain cell proliferation and survival. Although such cells are often histologically distinct from both the corresponding normal and invasive cancer cells of the same tissue origin, defining precancer remains a challenge for both the research and clinical communities. Once sufficient molecular and phenotypic changes have occurred in the precancer, the tissue is identified as a ‘cancer’ by a histopathologist. While even diagnosing cancer can at times be challenging, the determination of invasive cancer is generally less ambiguous and suggests a high likelihood of and potential for metastatic disease. The ‘hallmarks of cancer’ set out the fundamental organizing principles of malignant transformation but exactly how many of these hallmarks and in what configuration they define precancer has not been clearly and consistently determined. In this Expert Recommendation, we provide a starting point for a conceptual framework for defining precancer, which is based on molecular, pathological, clinical and epidemiological criteria, with the goal of advancing our understanding of the initial changes that occur and opportunities to intervene at the earliest possible time point.
"癌前病变"一词通常指的是肿瘤发展的早期阶段,由于分子和表型改变,该阶段与正常组织有区别,导致异常细胞至少部分自我维持,并在限制细胞增殖和存活的正常细胞线索之外发挥作用。尽管这些细胞在组织学上通常与同一组织来源的相应正常细胞和侵袭性癌细胞不同,但定义癌前病变对研究和临床界而言仍然是种挑战。一旦癌前病变发生足够的分子和表型变化,组织病理学家就会将该组织鉴定为“癌症”。尽管有时诊断癌症也很有挑战性,但侵袭性癌症的诊断通常不太含糊,并且表明转移性疾病的可能性和潜在性很高。“癌症特征”列出了恶性转化的基本组织原则,但这些特征中究竟有多少,以及它们以何种形式定义癌前病变,尚未得到明确和一致的确定。在本专家建议中,我们为定义癌前病变的概念框架提供了一个起点,该框架基于分子、病理、临床和流行病学标准,旨在加深我们对发生的初始变化的理解以及在最早的时间点进行干预的机会。